Turnover: ()
Country: France
Start up, Publicly traded healthcare research and development company
News
Valbiotis clinically validates the first anti-diabetic dietary supplement 17/09/2023
- Valbiotis has been developing a natural plant-based product for type 2 diabetes called Totum.63 for ten years.
- The company was founded in La Rochelle in 2014.
- Diabetes affects 537 million people worldwide, with 900 million pre-diabetics (International Diabetes Federation estimates in 2021).
- Valbiotis has invested €50 million in R&D to develop Totum.63.
- In 2020, the company signed a worldwide licensing agreement with Nestlé Health Science (NHS).
- NHS is to pay Valbiotis a lump sum of 4 million euros, bringing total payments to 7.5 million out of a potential 66 million, depending on commercial performance.
- The company is completing its study and preparing to launch its product in 2024.
- The company employs 50 people
Valbiotis regains control of its plant-based dietary supplements 25/10/2022
- Plant-based dietary supplements since 2014
- High-potential market: 250 billion worldwide by 2025, with annual growth of 9.6
Financial Data
DUNS: 800297194
Legal Name: VALBIOTIS
Address: RUE PAUL VATINE ZI DES QUATRE CHEVALIERS - BATIMENT F, 17180 PERIGNY
Number of employees: Entre 20 et 49 salariés (2020)
Capital: 974 386 EUR
Financial Data:
| Year | 2021 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Turnover | - | 88 810 | 2 657 | - |
| Gross margin (€) | 451 511 | 208 897 | 157 641 | 251 461 |
| EBITDA (€) | -9 007 131 | -5 692 357 | -2 771 853 | -932 492 |
| Operating profit (€) | -9 204 227 | -5 868 721 | -2 814 799 | -958 236 |
| Net profit (€) | -7 497 148 | -4 807 698 | -2 420 484 | -617 940 |
| Turnover growth rate (%) | - | 3 242,5 | - | -100 |
| Ebitda margin rate (%) | - | -6 409,6 | -104 322,7 | - |
| Operating margin rate (%) | - | -6 608,2 | -105 939 | - |
| Working Capital (turnover days) | - | 1 292,4 | 48 766 | - |
| Working Capital requirements (turnover days) | - | -2 799,4 | -38 488,2 | - |
| Net margin (%) | - | -5 413,5 | -91 098,4 | - |
| Added value / Turnover (%) | - | -3 705,8 | -70 390,8 | - |
| Wages and social charges (€) | 3 260 175 | 2 512 000 | 1 068 414 | 359 275 |
| Salaries / Turnover (%) | - | 2 828,5 | 40 211,3 | - |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président du directoire | Sébastien, Stéphane, Laurent, Franck | PELTIER | 47 | |
| Président du conseil de surveillance | Laurent, Samuel, Jean | LEVY | 53 | |
| Membre du directoire | Sébastien, Thierry, Marie | BESSY | 53 | |
| Membre du conseil de surveillance | Jean, Albert, Abraham | ZETLAOUI | 68 | |
| Membre du directoire | Pascal | SIRVENT | 45 | |
| Membre du directoire | Murielle | FAYAT | 57 | |
| Membre du conseil de surveillance | Agnes, Eliane, Pierrette | THOMAS | 61 |
Studies mentioning this company
The bioanalysis market - France
Other companies mentioned:
- Eurofins
- Carso groupe
- Mérieux NutriSciences
- SGS
- Intertek
- Bureau Veritas BV
- Phytocontrol
- Qualtech (IFBM Groupe)
- Valbiotis
- Abbott Groupe
- Agilent Technologies
- Beckman Coulter
- Bio-Rad Laboratories
- Genomic Vision
- LFB Groupe
- Novacyt
- Qiagen
- Randox Laboratories
- Roche Diagnostics France (Roche Group)
- Thermo Fisher Diagnostics